

Agnes Viale

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11628942/agnes-viale-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

26,372
citations

67
h-index

107
g-index

107
ext. papers

31,115
ext. citations

18.5
avg, IF

6
L-index

#	Paper	IF	Citations
104	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer. <i>Cancers</i> , 2022 , 14, 2397	6.6	1
103	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021 , 13, 96	14.4	8
102	Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules. <i>Cancer Research</i> , 2021 , 81, 2002-2014	10.4	4
101	NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. <i>Cancers</i> , 2021 , 13,	6.6	3
100	Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 3-9	5.1	23
99	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
98	Leveraging Systematic Functional Analysis to Benchmark an Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. <i>Cancer Research</i> , 2020 , 80, 4233-4243	10.1	9
97	Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1077-1085	12.9	37
96	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020 , 26, 1549-1556	50.5	118
95	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019 , 565, 654-658	50.4	214
94	Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2019 , 26, 1824-1832	3.1	21
93	SET: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 16	7.8	21
92	c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1509-1524	16.6	17
91	The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. <i>Cell</i> , 2019 , 178, 807-812	36.2	211
90	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019 , 571, 576-579	50.4	170
89	Lobular Carcinomas Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 674-686	12.9	31
88	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. <i>Blood</i> , 2019 , 133, 436-445	2.2	88

87	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 33, 125-136.e3	24.3	338
86	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018 , 24, 1965-1973	12.9	51
85	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018 , 8, 1540-1547	24.4	86
84	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018 , 34, 427-438.e6	24.3	339
83	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017 , 7, 1018-1029	24.4	201
82	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017 , 545, 452-456	25.4	413
81	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017 , 23, 4402-4415	12.9	69
80	Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with fusion-positive sarcomas. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	24
79	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 71, 405-414	10.2	132
78	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016 , 48, 356-8	36.3	111
77	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djv427	9.7	111
76	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. <i>Oncotarget</i> , 2016 , 7, 85430-85436	3.3	45
75	Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. <i>Haematologica</i> , 2016 , 101, e237-9	6.6	10
74	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2404-15	2.2	208
73	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell</i> , 2015 , 28, 15-28	24.3	105
72	Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. <i>Cancer Cell</i> , 2015 , 27, 502-15	24.3	145
71	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4099-105	2.2	75
70	Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. <i>Cancer Research</i> , 2015 , 75, 3713-9	10.1	38

69	NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. <i>Cancer Discovery</i> , 2015 , 5, 1178-93	24.4	78
68	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. <i>Nature Cell Biology</i> , 2015 , 17, 81-94	23.4	81
67	Precision microbiome reconstitution restores bile acid mediated resistance to <i>Clostridium difficile</i> . <i>Nature</i> , 2015 , 517, 205-8	50.4	1064
66	Somatic mutations in leukocytes infiltrating primary breast cancers. <i>Npj Breast Cancer</i> , 2015 , 1, 15005	7.8	18
65	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. <i>Oncotarget</i> , 2015 , 6, 36041-52	3.3	71
64	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. <i>PLoS ONE</i> , 2015 , 10, e0134731	3.7	26
63	Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. <i>Cancer Discovery</i> , 2014 , 4, 538-45	24.4	62
62	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. <i>Nature Genetics</i> , 2014 , 46, 588-94	36.3	124
61	Multi-platform assessment of transcriptome profiling using RNA-seq in the ABRF next-generation sequencing study. <i>Nature Biotechnology</i> , 2014 , 32, 915-925	44.5	169
60	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014 , 46, 1166-9	36.3	150
59	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014 , 124, 1174-82	2.2	531
58	Remodeling of the methylation landscape in breast cancer metastasis. <i>PLoS ONE</i> , 2014 , 9, e103896	3.7	25
57	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1379-91	16.6	26
56	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014 , 15, 454	18.3	224
55	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. <i>Nature Genetics</i> , 2014 , 46, 595-600	36.3	107
54	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. <i>Cancer Discovery</i> , 2014 , 4, 1014-21	24.4	98
53	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 1955-64	12.9	173
52	Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. <i>Acta Neuropathologica</i> , 2014 , 127, 747-59	14.3	21

51	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. <i>Nature Medicine</i> , 2013 , 19, 50-6	50.5	148
50	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
49	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3133-40	2.2	226
48	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013 , 45, 791-8	36.3	311
47	Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. <i>Cancer Discovery</i> , 2013 , 3, 520-33	24.4	266
46	Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4935-44	15.9	155
45	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. <i>Oncotarget</i> , 2013 , 4, 1729-36	3.3	171
44	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. <i>Nature Genetics</i> , 2012 , 44, 1179-81	36.3	552
43	Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. <i>Journal of Experimental Medicine</i> , 2012 , 209, 1445-56	16.6	247
42	Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , 2012 , 55, 905-14	11.6	561
41	Genome sequencing identifies a basis for everolimus sensitivity. <i>Science</i> , 2012 , 338, 221	33.3	546
40	Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3083-94		317
39	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2012 , 366, 1079-89	59.2	1378
38	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. <i>Nature</i> , 2012 , 483, 479-83	50.4	1373
37	Comparative genomic analysis of primary versus metastatic colorectal carcinomas. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2956-62	2.2	225
36	Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to <i>Clostridium difficile</i> -induced colitis. <i>Infection and Immunity</i> , 2012 , 80, 62-73	3.7	369
35	EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 434-42	8.9	15
34	Germline mutations in BAP1 predispose to melanocytic tumors. <i>Nature Genetics</i> , 2011 , 43, 1018-21	36.3	562

33	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. <i>Science Translational Medicine</i> , 2011 , 3, 90ra59	17.5	383
32	Genomic safe harbors permit high β globin transgene expression in thalassemia induced pluripotent stem cells. <i>Nature Biotechnology</i> , 2011 , 29, 73-8	44.5	249
31	Breast cancer methylomes establish an epigenomic foundation for metastasis. <i>Science Translational Medicine</i> , 2011 , 3, 75ra25	17.5	215
30	Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. <i>Cancer Research</i> , 2011 , 71, 5659-69	10.1	92
29	Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. <i>Clinical Cancer Research</i> , 2011 , 17, 122-33	12.9	33
28	Epigenomic reorganization of the clustered Hox genes in embryonic stem cells induced by retinoic acid. <i>Journal of Biological Chemistry</i> , 2011 , 286, 3250-60	5.4	78
27	Stat3 mediates expression of autotaxin in breast cancer. <i>PLoS ONE</i> , 2011 , 6, e27851	3.7	56
26	Identification of DOK genes as lung tumor suppressors. <i>Nature Genetics</i> , 2010 , 42, 216-23	36.3	91
25	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010 , 42, 715-21	36.3	521
24	Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. <i>Journal of Clinical Investigation</i> , 2010 , 120, 4332-41	15.9	577
23	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. <i>Nucleic Acids Research</i> , 2010 , 38, 6985-96	20.1	36
22	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 14903-8	11.5	383
21	(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 4519-24	11.5	444
20	Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. <i>Nature</i> , 2009 , 461, 402-6	50.4	701
19	BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. <i>Stem Cells</i> , 2009 , 27, 521-32	5.8	69
18	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008 , 14, 822-7	50.5	835
17	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 4340-5	11.5	256
16	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. <i>BMC Genetics</i> , 2008 , 9, 14	2.6	30

15	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20932-7	11.5	1395
14	Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. <i>Cancer Research</i> , 2007 , 67, 6626-36	10.1	186
13	Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. <i>Cancer Research</i> , 2005 , 65, 3063-71	10.1	122
12	Genes that mediate breast cancer metastasis to lung. <i>Nature</i> , 2005 , 436, 518-24	50.4	2242
11	Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. <i>Journal of Investigative Dermatology</i> , 2005 , 124, 412-8	4.3	52
10	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. <i>Clinical Cancer Research</i> , 2005 , 11, 565-72	12.9	116
9	Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. <i>Clinical Cancer Research</i> , 2004 , 10, 5792-803	12.9	88
8	Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1775-81	2.2	152
7	Segmental duplications in euchromatic regions of human chromosome 5: a source of evolutionary instability and transcriptional innovation. <i>Genome Research</i> , 2003 , 13, 369-81	9.7	47
6	Structure and expression of the variant melanin-concentrating hormone genes: only PMCHL1 is transcribed in the developing human brain and encodes a putative protein. <i>Molecular Biology and Evolution</i> , 2000 , 17, 1626-40	8.3	24
5	Effects of leptin on melanin-concentrating hormone expression in the brain of lean and obese Lep(ob)/Lep(ob) mice. <i>Neuroendocrinology</i> , 1999 , 69, 145-53	5.6	52
4	Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals. <i>Journal of Biological Chemistry</i> , 1999 , 274, 6536-45	5.4	50
3	17beta-estradiol regulation of melanin-concentrating hormone and neuropeptide-E-I contents in cynomolgus monkeys: a preliminary study. <i>Peptides</i> , 1999 , 20, 553-9	3.8	23
2	Structure, expression, and evolution of the variant MCH gene in primates. <i>Annals of the New York Academy of Sciences</i> , 1998 , 839, 214-8	6.5	1
1	The melanin-concentrating hormone gene in human: flanking region analysis, fine chromosome mapping, and tissue-specific expression. <i>Molecular Brain Research</i> , 1997 , 46, 243-55		55